OPN-6602

N/A

Report date: 2026/04/16 17:53:15
NME

Base Information

Drug NameOPN-6602
Drug Alias NameOPN-6602
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone acetyltransferase p300 inhibitorscAMP-response element binding protein inhibitors
TargetsHistone acetyltransferase p300cAMP-response element binding protein
Therapy Area/IndicationsProstatic NeoplasmsMultiple MyelomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPlexxikon Inc
China Registration ClassN/A

Develop Information

Active CompaniesOpna Bio LLCOpna Bio SA
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsMultiple MyelomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A